会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Analyte monitoring system with a device for promoting bodily fluid expression from a target site
    • 分析物监测系统,具有用于从目标部位促进体液表达的装置
    • US20070073187A1
    • 2007-03-29
    • US11236050
    • 2005-09-26
    • Anne ThomsonManuel Alvarez-IcazaWilma Gordon
    • Anne ThomsonManuel Alvarez-IcazaWilma Gordon
    • A61B5/00
    • An analyte monitoring system for the determination of an analyte in a bodily fluid sample includes a housing, a meter for the determination of an analyte in a bodily fluid sample, and a device for promoting the expression of the bodily fluid sample from a target site. The device for promoting expression of bodily fluid has a pressure application mechanism for urging bodily fluid toward the target site attached to the housing. In addition, the pressure application mechanism is configured for urging the bodily fluid by sequentially increasing an area of contact and applied pressure between the pressure application mechanism and the user's body in the vicinity of the target site with the area of contact and applied pressure sequentially increasing in a direction toward the target site.
    • 用于测定体液样品中的分析物的分析物监测系统包括壳体,用于测定体液样品中的分析物的仪表,以及用于促进体液样品从靶位点表达的装置。 用于促进体液表达的装置具有用于将体液推向连接到壳体的目标部位的压力施加机构。 此外,压力施加机构构造成通过在接触面积和施加压力依次增加的情况下依次增加目标部位附近的压力施加机构和使用者身体之间的接触面积和施加压力来推压体液 朝向目标地点的方向。
    • 3. 发明申请
    • Allelic variants of grp50
    • grp50的等位变体
    • US20050142548A1
    • 2005-06-30
    • US10484096
    • 2002-07-08
    • Anne ThomsonDonald, Robert Dunbar
    • Anne ThomsonDonald, Robert Dunbar
    • G01N33/50C07K14/705C07K14/72C12N1/15C12N1/19C12N1/21C12N5/10C12N15/09C12Q1/68G01N33/15C07H21/04
    • C07K14/723
    • The present invention provides isolated polynucleotides encoding a receptor gene called GPR50 having at least one polymorphic sites. It furthermore provides a method for analysing polimorphic sites in said receptor gene. Certain of these polynucleotides having a polymorphic site (allelic variants) are found to be more prevalent in a population of patients with clinical Bipolar Depression compared to a control population. A method for the genetic testing of Bipolar Depression is a further embodiment of the present invention. Furthermore, polynucleotides encompassing these polymorphic sites, the invariant distal or proximal to the polymorphic site localized polynucleotides as well as the polynucleotides encoding GPR50 are part of the invention. The present invention also provides a recombinant cell line expressing these novel receptors at appropriate levels such that novel compounds active at these receptors may be identified for therapeutic use.
    • 本发明提供了编码具有至少一个多态位点的称为GPR50的受体基因的分离的多核苷酸。 此外还提供了一种分析所述受体基因中的突变位点的方法。 发现具有多态位点(等位基因变体)的这些多核苷酸中的某些与对照群体相比,在具有临床双相抑郁症的患者群体中更普遍。 双极抑郁基因检测方法是本发明的另一个实施方案。 此外,包括这些多态性位点的多核苷酸,多态位点局部多核苷酸的远端或近端的不变量以及编码GPR50的多核苷酸是本发明的一部分。 本发明还提供以适当水平表达这些新受体的重组细胞系,使得可以鉴定在这些受体上活化的新化合物用于治疗用途。
    • 5. 发明申请
    • Cap for a dermal tissue lancing device
    • 用于皮肤组织穿刺装置的盖
    • US20060184189A1
    • 2006-08-17
    • US10706166
    • 2003-11-12
    • Lorin OlsonAnne ThomsonDamian BaskeyfieldChristopher LeachRichard DaySebastian Bohm
    • Lorin OlsonAnne ThomsonDamian BaskeyfieldChristopher LeachRichard DaySebastian Bohm
    • A61B17/32
    • A61B5/157A61B5/150022A61B5/150068A61B5/150183A61B5/150358A61B5/150412A61B5/150503A61B5/15186
    • A cap for use with a dermal tissue lancing device (that includes a housing and a lancet movable with respect to the housing) includes a proximal end for engaging with the housing, a distal end for engaging with dermal tissue and an opening for a portion of the lancet to pass through. The distal end of the cap includes portions for engaging dermal tissue. These portions are resiliently deformable such that, when the cap contacts and is urged towards dermal tissue, the portions deform resiliently, engaging the dermal tissue and approaching theretogether. A process for the collection of a fluid sample (e.g., blood) from dermal tissue includes providing a dermal tissue lancing device with a housing, a cap and a lancet that is moveable with respect to the housing and the cap. The cap includes a proximal end for engaging with the housing, a distal end for engaging with dermal tissue, and an opening for a portion of the lancet to pass through. The distal end of the cap includes resiliently deformable portions for engaging dermal tissue. Next, the cap is contacted with the dermal tissue (e.g., dermal tissue of a fingertip, limb, or abdomen) such that the portions engage the dermal tissue. Subsequently, the cap is urged towards the dermal tissue such that at least first and second portions deform resiliently and approach theretogether to create a bulge in the dermal tissue. The bulge is then lanced to create a puncture from which a fluid sample is collected.
    • 用于真皮组织穿刺装置(包括壳体和相对于壳体可移动的刺血针)的帽包括用于与壳体接合的近端,用于与真皮组织接合的远端和用于部分 刺血针通过。 帽的远端包括用于接合皮肤组织的部分。 这些部分是可弹性变形的,使得当帽接触并被推向真皮组织时,这些部分弹性变形,与真皮组织接合并且一起接近。 用于从真皮组织收集流体样品(例如血液)的方法包括提供真皮组织切割装置,其具有可相对于壳体和盖移动的壳体,帽和刺血针。 盖包括用于与壳体接合的近端,用于与真皮组织接合的远端和用于刺血针的一部分通过的开口。 盖的远端包括用于接合皮肤组织的弹性变形部分。 接下来,将盖与真皮组织(例如,指尖,肢体或腹部的真皮组织)接触,使得这些部分接合皮肤组织。 随后,将帽推向真皮组织,使得至少第一和第二部分弹性变形并且一起接近以在真皮组织中产生凸起。 然后将凸起切开以产生从中收集流体样品的穿刺。
    • 6. 发明申请
    • Allelic variants of GPR50
    • GPR50的等位变体
    • US20070117146A1
    • 2007-05-24
    • US11699874
    • 2007-01-30
    • Anne ThomsonDonald Dunbar
    • Anne ThomsonDonald Dunbar
    • C12Q1/68C07H21/04C12P21/06C07K14/705
    • C07K14/723
    • The present invention provides isolated polynucleotides encoding a receptor gene called GPR50 having at least one polymorphic sites. It furthermore provides a method for analyzing polymorphic sites in the receptor gene. Certain of these polynucleotides having a polymorphic site (allelic variants) are found to be more prevelant in a population of patients with clinical Bipolar Depression compared to a control population. A method for the genetic testing of Bipolar Depression is a further embodiment of the present invention. Furthermore, polynucleotides encompassing these polymorphic sites, the invariant distal or proximal to the polymorphic site localized polynucleotides as well as the polynucleotides encoding CPR50 are part of the invention. The present invention also provides a recombinant cell line expressing these novel receptors at appropriate levels such that novel compounds active at these receptors may be identified for therapeutic use.
    • 本发明提供了编码具有至少一个多态位点的称为GPR50的受体基因的分离的多核苷酸。 此外,还提供了用于分析受体基因中的多态位点的方法。 发现具有多态性位点(等位基因变体)的这些多核苷酸中的某些与对照群体相比,在具有临床双相抑郁症的患者群体中更具优势。 双极抑郁基因检测方法是本发明的另一个实施方案。 此外,包括这些多态性位点的多核苷酸,多态性位点定位多核苷酸的远端或近端以及编码CPR50的多核苷酸的多核苷酸是本发明的一部分。 本发明还提供以适当水平表达这些新受体的重组细胞系,使得可以鉴定在这些受体上活化的新化合物用于治疗用途。